Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New styryl sulfones as anticancer agents.

Manohar Sharma Vedula1, Aravind Babu Pulipaka, Chandrasekhar Venna

  • 1Discovery Chemistry, Discovery Research, Dr. Reddy's Laboratories, Bollaram Road, 500 050, Hyderabad, India. sarmavm@dreddys.com

European Journal of Medicinal Chemistry
|October 17, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End-Stage Kidney Disease on Hemodialysis.

Journal of clinical pharmacology·2026
Same author

Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma.

Blood·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

What Does an Editor Do in 2025?

Clinical pharmacology in drug development·2025
Same author

Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects.

Journal of clinical pharmacology·2025
Same author

Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients.

Journal of clinical pharmacology·2025
This summary is machine-generated.

New styryl sulfone compounds were synthesized and tested for anti-proliferative effects. Compound 7k demonstrated significant tumor growth inhibition in a human carcinoma mouse model.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Cancer remains a leading cause of mortality worldwide.
  • Developing novel anti-cancer therapeutics is crucial for improving patient outcomes.
  • Styryl sulfone derivatives represent a class of compounds with potential anti-proliferative properties.

Purpose of the Study:

  • To synthesize novel styryl sulfone compounds.
  • To evaluate the anti-proliferative activity of these compounds.
  • To identify lead compounds for further cancer drug development.

Main Methods:

  • Synthesis of a library of styryl sulfone derivatives.
  • In vivo anti-cancer efficacy testing in a mouse model.
  • Administration of compounds via oral gavage.

Related Experiment Videos

Main Results:

  • Several styryl sulfone compounds were successfully synthesized.
  • Compound 7k exhibited significant anti-proliferative activity.
  • Compound 7k achieved 51% tumor growth inhibition in HT-29 human carcinoma-implanted mice at 400 mg kg(-1) orally.

Conclusions:

  • Styryl sulfone compounds show promise as anti-cancer agents.
  • Compound 7k is a potent inhibitor of HT-29 human carcinoma growth.
  • Further investigation of compound 7k is warranted for its potential as a therapeutic agent.